Moderna’s mRNA-Based RSV Vaccine Reports High Rate of Adverse Reactions in New Study

An mRNA vaccine for respiratory syncytial virus (RSV) developed by Moderna has caused higher adverse reactions compared to unvaccinated individuals in a clinical trial. The study, published in the New England Journal of Medicine on Dec. 14, detailed a randomized test involving 35,541 individuals aged 60 years and older, out of which roughly half were given the mRNA-1345 vaccine (Moderna’s RSV vaccine) while the remaining received a placebo. The trials reported 95 cases of RSV among the placebo group and 29 cases among the vaccinated group, suggesting that the vaccine prevented 66 infections. Funded by Moderna, the study conclusion claimed, “A single dose of the mRNA-1345 vaccine resulted in no evident safety concerns and led to a lower incidence of RSV-associated lower respiratory tract disease and of RSV-associated acute respiratory disease than placebo among adults 60 years of age or older.”...